Trials / Completed
CompletedNCT05873426
Mass Balance Study of [14C]ZSP1273 in Healthy Adult Male Subjects in China
Single-center, Open-label, Non-randomized and Single-dose Clinical Trial to Explore the Mass Balance of Oral Suspension of 600mg [14C]ZSP1273
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This study is a single-center, open-label, and single-dose clinical study to evaluate the mass balance, biotransformation and pharmacokinetics of \[14C\]ZSP1273 in healthy Chinese male participants, revealing the overall pharmacokinetic characteristics of ZSP1273.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C] ZSP1273 | 600 mg suspension containing 50μCi of \[14C\]ZSP1273 |
Timeline
- Start date
- 2023-03-25
- Primary completion
- 2023-04-28
- Completion
- 2023-04-28
- First posted
- 2023-05-24
- Last updated
- 2025-03-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05873426. Inclusion in this directory is not an endorsement.